Killer cell immunoglobulin-like receptors in Thai patients with multiple myeloma

被引：4

作者：

Theeranawakam, Aphiradee ^{[1
]}

Vejbaesya, Sasijit ^{[1
,3
]}

Khuhapinant, Archrob ^{[2
]}

Sae-Tam, Pradermchai ^{[1
]}

机构：

[1] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Transfus Med, Bangkok, Thailand

[2] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Med, Bangkok, Thailand

[3] Mahidol Univ, Siriraj Hosp, Fac Med, Departmrnt Transfus Med, 2 Wanglang Rd, Bangkok 10700, Thailand

来源：

ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY | 2024年 / 42卷 / 01期

关键词：

KIR; multiple myeloma; Thai; NK cell; HLA ligand; CLASS-I; KIR; DIVERSITY; PCR;

D O I：

10.12932/AP-130520-0842

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Background: Natural killer (NK) cells have been implicated in the immune response against multiple myeloma (MM) cells. Killer cell immunoglobulin-like receptors (KIRs) regulate NK cell activity by recognizing specific human leukocyte antigen (HLA) class I as ligands. Objective: To investigate the association of KIR genes and ligands with MM in the Thai population. Methods: KIR gene polymorphisms and their HLA ligands were investigated in 66 Thai patients with MM and 200 healthy controls. Results: The frequencies of KIR3DL1 and 2DS4 were significantly lower in myeloma patients than in controls (P = 0.02). The frequencies of KIR3DL1, 2DS4, 2DL1 with C2, and 3DL1 with Bw4 were significantly higher in the patients achieving > very good partial response (VGPR) than those achieving <= VGPR after treatment with bortezomib (P = 0.009, 0.009, 0.01, and 0.02, respectively). Conclusion: This study suggests the association of KIR genes with the protection against MM and the association of inhibitory KIR and ligands with the response to treatment in MM.

引用

页码：77 / 80

页数：4

共 24 条

[1] The Impact of KIR Polymorphism on the Risk of Developing Cancer: Not as Strong as Imagined? [J].

Augusto, Danillo G. .

FRONTIERS IN GENETICS, 2016, 7

[2] Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population [J].

Bontadini, A. ;

Testi, M. ;

Cuccia, M. C. ;

Martinetti, M. ;

Carcassi, C. ;

Chiesa, A. ;

Cosentini, E. ;

Dametto, E. ;

Frison, S. ;

Iannone, A. M. ;

Lombardo, C. ;

Malagoli, A. ;

Mariani, M. ;

Mariotti, L. ;

Mascaretti, L. ;

Mele, L. ;

Miotti, V. ;

Nesci, S. ;

Ozzella, G. ;

Piancatelli, D. ;

Romeo, G. ;

Tagliaferri, C. ;

Vatta, S. ;

Andreani, M. ;

Conte, R. .

JOURNAL OF TRANSLATIONAL MEDICINE, 2006, 4 (1)

[3] Phototyping: Comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP) [J].

Bunce, M ;

ONeill, CM ;

Barnardo, MCNM ;

Krausa, P ;

Browning, MJ ;

Morris, PJ ;

Welsh, KI .

TISSUE ANTIGENS, 1995, 46 (05) :355-367

[4] Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci [J].

Carrington, M ;

Wang, S ;

Martin, MP ;

Gao, XJ ;

Schiffman, M ;

Cheng, J ;

Herrero, R ;

Rodriguez, AC ;

Kurman, R ;

Mortel, R ;

Schwartz, P ;

Glass, A ;

Hildesheim, A .

JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (07) :1069-1075

[5] Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy [J].

Delgado, David C. ;

Hank, Jacquelyn A. ;

Kolesar, Jill ;

Lorentzen, David ;

Gan, Jacek ;

Seo, Songwon ;

Kim, KyungMann ;

Shusterman, Suzanne ;

Gillies, Stephen D. ;

Reisfeld, Ralph A. ;

Yang, Richard ;

Gadbaw, Brian ;

DeSantes, Kenneth B. ;

London, Wendy B. ;

Seeger, Robert C. ;

Maris, John M. ;

Sondel, Paul M. .

CANCER RESEARCH, 2010, 70 (23) :9554-9561

[6] Genetic diversity of KIR natural killer cell markers in populations from france, guadeloupe, finland, senegal and reunion [J].

Denis, L ;

Sivula, J ;

Gourraud, PA ;

Kerdudou, N ;

Chout, R ;

Ricard, C ;

Moisan, JP ;

Gagne, K ;

Partanen, J ;

Bignon, JD .

TISSUE ANTIGENS, 2005, 66 (04) :267-276

[7] Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab [J].

Erbe, Amy K. ;

Wang, Wei ;

Carmichael, Lakeesha ;

Hoefges, Anna ;

Grzywacz, Bartosz ;

Reville, Patrick K. ;

Ranheim, Erik A. ;

Hank, Jacquelyn A. ;

Kim, KyungMann ;

Seo, Songwon ;

Mendonca, Eneida A. ;

Song, Yiqiang ;

Kenkre, Vaishalee P. ;

Hong, Fangxin ;

Gascoyne, Randy D. ;

Paietta, Elisabeth ;

Horning, Sandra J. ;

Miller, Jeffrey S. ;

Kahl, Brad ;

Sondel, Paul M. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

[8] Report from the Eleventh Killer Immunoglobulin-like Receptor (KIR) Workshop: Novel insights on KIR polymorphism, ligand recognition, expression and function [J].

Falco, Michela ;

Sivori, Simona ;

Meazza, Raffaella ;

Pende, Daniela .

HLA, 2019, 94 (02) :100-110

[9] Translating the anti-myeloma activity of Natural Killer cells into clinical application [J].

Fionda, Cinzia ;

Stabile, Helena ;

Molfetta, Rosa ;

Soriani, Alessandra ;

Bernardini, Giovanni ;

Zingoni, Alessandra ;

Gismondi, Angela ;

Paolini, Rossella ;

Cippitelli, Marco ;

Santoni, Angela .

CANCER TREATMENT REVIEWS, 2018, 70 :255-264

[10] Anti-myeloma activity of natural killer lymphocytes [J].

Frohn, C ;

Höppner, M ;

Schlenke, P ;

Kirchner, H ;

Koritke, P ;

Luhm, J .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (03) :660-664

← 1 2 3 →